Click Therapeutics is a specialist in digital therapeutics and has raised about $17 million in its latest financing.
July 27, 2018
Click Therapeutics has received about $17 million in a financing round led by Sanofi Ventures. The NY-based company is a specialist in digital therapeutic solutions such as prescription medical treatments.
The company has a commercial product for smoking cessation. About two years ago, Click partnered with Magellan Health to create enhance its smoking cessation program. In addition, Click is developing prescription digital therapeutics for the treatment of depression (CT-152), insomnia (CT-141), acute coronary syndrome (CT-111), and chronic pain (CT-130).
Click said it will seek FDA clearance for these programs as class II medical devices with disease-specific treatment claims, to be prescribed by physicians and reimbursed by payers.
“The Click Therapeutics team is proud to partner with Sanofi Ventures to advance our pipeline and expand our product portfolio of prescription medical treatments,” remarked David Benshoof Klein, Co-founder and CEO of Click said in a release. “As we announced last summer, in 2017 we expanded our collaboration with Magellan Health. to pursue regulatory clearance from FDA for indication-specific prescription digital therapies, leveraging the industry-leading suite of intellectual property and data from Magellan’s existing software as well as their vast coverage and reimbursement leadership. The addition of Sanofi as a strategic investor, and the closing of this financing, represent major steps forward for Click and for the field of software as prescription medical treatments. By connecting patients with cognitive and neurobehavioral interventions, our platform will bring clinically-validated digital therapeutic solutions into mainstream healthcare.”
About the Author(s)
You May Also Like